ReviewMedical science monitor : international medical journal of experimental and clinical research2025
A Review of Modulation of Gut Microbiota to Mitigate Gestational Diabetes: Implications for Maternal and Child Health.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developmental Programming of Drug Response: Microbiota as a Missing Dimension in Perinatal Drug Discovery.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of gestational diabetes mellitus (GDM) is a pressing global public health concern. Despite extensive identification of GDM risk factors and the implementation of screening programs, there has been a notable lack of significant reduction in maternal, fetal, and neonatal complications. It is vital to recognize that the health trajectory of future generations begins before birth, during intrauterine life and even before conception. The development of 'diabetogenic' and 'obesogenic' changes in the DNA of offspring can be triggered not only by adverse intrauterine conditions, but also by changes in germ cell DNA at earlier stages. Accumulating evidence suggests that the increasing prevalence and persistent metabolic effects of GDM may be mediated by epigenetic modifications. The composition of the human gut microbiota is emerging as a key determinant of human metabolic processes. Consequently, dysbiosis of the gut microbiota via epigenetic mechanisms may contribute to metabolic complications in both the mother and the developing fetus. Given that diet plays a critical role in maintaining a healthy microbiota profile and that certain epigenetic alterations are reversible, it is pertinent to emphasize that not only the pregnant woman but also both partners attempting conception could influence the future health of the child. The aim of this article is to review the role of gut microbiota modulation in preventing and managing gestational diabetes mellitus and the health benefits for mother and child.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.